KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Inventory: 2012-2025

Historic Change in Inventory for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Sep 2025 value amounting to $12.9 million.

  • Supernus Pharmaceuticals' Change in Inventory rose 381.06% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135,000, marking a year-over-year increase of 100.77%. This contributed to the annual value of -$15.8 million for FY2024, which is 158.69% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Change in Inventory stood at $12.9 million, which was up 364.78% from -$4.9 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Change in Inventory registered a high of $12.9 million during Q3 2025, and its lowest value of -$6.9 million during Q3 2023.
  • In the last 3 years, Supernus Pharmaceuticals' Change in Inventory had a median value of -$4.6 million in 2024 and averaged -$1.7 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Change in Inventory spiked by 2,606.67% in 2021 and then tumbled by 251.42% in 2024.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Change in Inventory stood at $5.2 million in 2021, then surged by 120.12% to $11.6 million in 2022, then plummeted by 143.52% to -$5.0 million in 2023, then skyrocketed by 36.61% to -$3.2 million in 2024, then spiked by 381.06% to $12.9 million in 2025.
  • Its last three reported values are $12.9 million in Q3 2025, -$4.9 million for Q2 2025, and -$4.7 million during Q1 2025.